{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells\nDose: 1x10^6 cells/Kg",
            "3 times with 2-week intervals by IV infusion."
      ],
      "ArmGroupInterventionName": [
            "Biological: SCM-AGH",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "SCM-AGH",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04179760"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study consists of two phases (Phase I and Phase II). Phase II will be conducted sequentially after the safety of SCM-AGH is secured in Phase I.\n\nPhase I: Multicenter in Korea, Randomized, Open-label, Parallel arm Phase II: Multicenter in Korea, Double-blind, Placebo-controlled, Parallel arm"
      ],
      "BriefTitle": [
            "Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis"
      ],
      "CentralContactEMail": [
            "hher@scmlifescience.com"
      ],
      "CentralContactName": [
            "Howard Her"
      ],
      "CentralContactPhone": [
            "+8200000000"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 30, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Dermatitis, Atopic"
      ],
      "ConditionAncestorId": [
            "D000012871",
            "D000012873",
            "D000030342",
            "D000017443",
            "D000006969",
            "D000006967",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Skin Diseases",
            "Skin Diseases, Genetic",
            "Genetic Diseases, Inborn",
            "Skin Diseases, Eczematous",
            "Hypersensitivity, Immediate",
            "Hypersensitivity",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC16",
            "BC17",
            "BC20",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Diseases and Abnormalities at or Before Birth",
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Dermatitis, Atopic",
            "Dermatitis"
      ],
      "ConditionBrowseLeafId": [
            "M6223",
            "M6219",
            "M6807",
            "M14826",
            "M14828",
            "M22839",
            "M18864",
            "M9170",
            "M9172",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Dermatitis, Atopic",
            "Dermatitis",
            "Eczema",
            "Skin Diseases",
            "Skin Diseases, Genetic",
            "Genetic Diseases, Inborn",
            "Skin Diseases, Eczematous",
            "Hypersensitivity",
            "Hypersensitivity, Immediate",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003876",
            "D000003872"
      ],
      "ConditionMeshTerm": [
            "Dermatitis, Atopic",
            "Dermatitis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Phase I: Multicenter in Korea, Randomized, Open-label, Parallel arm Phase II: Multicenter in Korea, Double-blind, Placebo-controlled, Parallel arm"
      ],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Phase I (Multicenter, Randomized, Open-label, Parallel arm Design) Twenty subjects with moderate to severe Atopic Dermatitis(AD) are planned to be enrolled from 6 sites in Korea and administered with SCM-AGH by intravenous (IV) infusion 3 times at two-week intervals and evaluated for safety during the safety evaluation period (12 weeks after first infusion).\n\nPhase II (Multicenter, Double-blind, Placebo-controlled, Parallel arm) Phase II of the study is randomized, double-blind, placebo-controlled, parallel arm comparison study in adult subjects with moderate to severe AD. 72 subjects with moderate to severe AD are planned to be enrolled from 6 sites in Korea. Following up to a 4-week Screening period, subjects will be randomly assigned to one of the following treatment arms: SCM-AGH or placebo in the ratio of 1:1."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nSubjects who are males or females aged >= 19 years\n\nSubjects who are diagnosed with Atopic Dermatitis (AD) based on the Eichenfield revised criteria of Hannifin and Rajka that\n\nhas been present for at least 1 year before the Screening visit, and\nhave chronic AD symptoms continually for at least 6 months before Screening visit\nSubjects who have moderate to severe AD (EASI \u226516) at the Screening visit and Baseline visit\nSubjects who have IGA score \u22653 at the Screening and Baseline visits\nSubjects who have at least 10% of total body surface area affected by AD at the Screening and Baseline visits\nSubjects who can give written informed consent\nSubjects must have applied a stable dose of a bland emollient to affected areas for at least 7 days before the Baseline visit and be willing to continue for the duration of the study\nMale subjects must abstain from heterosexual activities or agree to use a condom through 30 days after the final dose of study drug. Women of childbearing potential (WOCBP) must abstain from heterosexual activities or agree to use effective contraception through 30 days after the final dose of study drug.\n\nEffective contraception for males and/or WOCBP includes:\n\nBlockage methods - spermicides and condoms/spermicides and vaginal diaphragm for contraception, vaginal sponges or cervical cap (where available)\nOral contraceptives (\"the pill\") for at least 1 month\nDepot or injectable birth control or implantable contraception (e.g., Implanon)\nIntrauterine device (IUD)\nDocumented evidence of surgical sterilization at least 6 months prior to Screening visit i.e., tubal ligation or hysterectomy for women or vasectomy for men\nWomen who are post-menopausal, as documented by measurement of follicle stimulating hormone\n\nExclusion Criteria:\n\nSystemic infection or local infection requiring prohibited medications at Screening visit\n\nSubjects who underwent the following treatments within 4 weeks prior to Baseline visit or are scheduled to receive the following treatments within 4 weeks from Baseline at the discretion of investigator:\n\nUse of immunosuppressive/ immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-\u03b3 (interferon-gamma), Janus kinase inhibitors, azathioprine, methotrexate)\nPhototherapy for AD\nAny other systemic therapy used to treat AD or symptoms of AD (approved or off-label use)\nUse of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within at least 2 weeks prior to Baseline\nHistory of anaphylaxis to any biologic therapy or vaccine\nHistory of Guillain-Barr\u00e9 syndrome\nReceipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained\nAny allergen immunotherapy within 4 months prior to or throughout the study\nA value outside the specified range of 90 mmHg - 140 mmHg for systolic blood pressure and 50 mmHg -90 mmHg for diastolic blood pressure (both inclusive) at Screening (can be repeated once at Screening as per Principal Investigator's [PI's] discretion).\nReceipt of live vaccines within 12 weeks prior to Baseline\n\nReceipt of the following biologics:\n\nCell depleting agents such as rituximab: within 6 months prior to Baseline or within time to return of lymphocyte count to normal, whichever is longer\nOther biologics: within 5 half-lives or within 16 weeks prior to Baseline, whichever is longer\nActive infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus (HCV)\nFemale subjects who are pregnant or lactating or female subjects of childbearing potential who have a pregnancy plan or do not agree to use acceptable methods of contraception, excluding females who are in post-menopausal or surgically infertile (bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy)\nReceipt of any investigational drugs within 8 weeks prior to baseline, within 5 half lives of investigational drug or participated in any clinical trials of medical device\nDiagnosed with either primary or recurrent malignancy within 5 years from Screening\nLiver malfunctions with aspartate aminotransferase (AST) / alanine aminotransferase (ALT) level >2x upper limit of normal (ULN) at Screening\nRenal malfunctions with creatinine level >2x ULN at Screening\nQTc (corrected QT interval) prolongation >470 msec or other significant ECG abnormality noted within 14 days of treatment\nHistory of hypersensitivity to antibiotics and antimicrobial agents\nHistory of significant Adverse Events (AEs) during stem cell therapies\nAllergic or hypersensitivity reaction to the IP (Investigational Product), drug of similar class or ingredients [bovine serum, dimethyl sulfoxide (DMSO)]\nFailure to comply with emollient application instructions prior to baseline, per diary\nSubjects who, in the opinion of the investigator, have other unstable intercurrent diseases that confound safety and efficacy assessment\nPlanned or anticipated major surgical procedure during the subject's participation in this study\nSubjects who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures"
      ],
      "EnrollmentCount": [
            "92"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "SCM-AGH",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).",
            "Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4)."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "SCM-AGH",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "November 19, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "November 17, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "SCM Lifescience Co., LTD."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Incheon"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Gwang Seong Choi, MD-Ph.D."
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "Korea, Republic of"
      ],
      "LocationFacility": [
            "Inha University Hospital"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [],
      "MaximumAge": [],
      "MinimumAge": [
            "19 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Phase I/II Trial to Evaluate the Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "SCM Lifescience Co., LTD."
      ],
      "OrgStudyId": [
            "ADT2002"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Inha University Hospital"
      ],
      "OverallOfficialName": [
            "Gwang Seong Choi, MD-Ph.D"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "June 30, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome."
      ],
      "PrimaryOutcomeMeasure": [
            "over 50% reduction ratio of Eczema Area and Severity Index (EASI) as contrasted with baseline value (EASI-50)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Week 12"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
            "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
            "An EASI score is a tool used to measure the extent (area) and severity of atopic eczema (Eczema Area and Severity Index). The minimum EASI score is 0 and the maximum EASI score is 72. Higher scores mean worse outcome.",
            "This assessment is the overall investigator's overall global assessment for the whole body. Minimum 0 to Maximum 4. 0 means No inflammatory signs of atopic dermatitis, 4 means Marked erythema & Disease is widespread in extent.",
            "This assessment is the overall investigator's overall global assessment for the whole body. Minimum 0 to Maximum 4. 0 means No inflammatory signs of atopic dermatitis, 4 means Marked erythema & Disease is widespread in extent.",
            "The NRS is comprised of two items and represents the numbers 0 (\"no itch\") to 10 (\"worst imaginable itch\") in the average score of itch and the worst score of itch.",
            "The NRS is comprised of two items and represents the numbers 0 (\"no itch\") to 10 (\"worst imaginable itch\") in the average score of itch and the worst score of itch.",
            "BSA involvement of AD will be assessed for each part of the body using \"Wallace rule of nines\". This BSA is not calculated by weight and height unlike usual BSA calculation, the Wallace rule of nines is a tool used in pre-hospital and emergency medicine to estimate the total body surface area (BSA) affected by a burn. However, this study, the rule of nines will be used to measure the estimated BSA of atopic dermatitis.",
            "SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective. Maximum value is up to 103 which is the worst outcome.",
            "The Dermatology Life Quality Index questionnaire is designed for use in adults. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.",
            "POEM scores are 0-2 (clear/almost clear); 3-7 (mild); 8-16 (moderate); 17-24 (severe); 25-28 (very severe)",
            "biomarkers will be evaluated from the baseline to each time point. Unit of Measure is IU/mL.",
            "biomarkers will be evaluated from the baseline to each time point. Unit of measure is cells/\u03bcL.",
            "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
            "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
            "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL.",
            "biomarkers will be evaluated from the baseline to each time point. Unit of measure is pg/mL."
      ],
      "SecondaryOutcomeMeasure": [
            "Score change from Baseline in Eczema Area and Severity Index(EASI) score",
            "Percentage of subjects who have EASI-75 (improvement of \u226575% in EASI score from Baseline)",
            "Percentage of subjects who have EASI-90 (improvement of \u226590% in EASI score from Baseline)",
            "Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1",
            "Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more",
            "Score change from Baseline on Pruritus Numerical Rating Scale (NRS)",
            "Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more",
            "Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)",
            "Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index",
            "Score change from Baseline in the Dermatology Life Quality Index (DLQI)",
            "Score change from Baseline the Patient-Oriented Eczema Measure (POEM)",
            "Change from Baseline in biomarker (Immunoglobulin E [IgE])",
            "Change from Baseline in biomarker (eosinophil count)",
            "Change from Baseline in biomarker (interleukin [IL]-13)",
            "Change from Baseline in biomarker (interleukin [IL]-17)",
            "Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])",
            "Change from Baseline in biomarker (interleukin [IL]-22)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Weeks 12, 16, 20 and 24",
            "Weeks 12, 16, 20 and 24",
            "Weeks 12, 16, 20 and 24",
            "Weeks 12, 16, 20 and 24",
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Weeks 12, 16, 20 and 24",
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Weeks 4, 8, 12, 16, 20 and 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24",
            "Week 4, Week 6, Week 8, Week 12, Week 16, Week 20 and Week 24"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 24, 2020"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "November 27, 2019"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "November 20, 2019"
      ]
}